Other equities research analysts have also recently issued reports about the stock. Analysts at Ladenburg Thalmann downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $19.00 price target on the stock. Separately, analysts at Robert W. Baird downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $17.00 price target on the stock, down previously from $21.00. Finally, analysts at Jefferies Group (NYSE: JEF) reiterated an “underperform” rating on shares of AMAG Pharmaceuticals in a research note to investors on Tuesday, March 6th.
Shares of AMAG Pharmaceuticals traded down 0.74% during mid-day trading on Friday, hitting $13.152. AMAG Pharmaceuticals has a 52 week low of $12.65 and a 52 week high of $19.62. The company’s market cap is $280.9 million.
AMAG Pharmaceuticals last announced its earnings results on Tuesday, May 1st. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.63) by $0.05. The company’s quarterly revenue was up 15.7% on a year-over-year basis. On average, analysts predict that AMAG Pharmaceuticals will post $0.31 earnings per share next quarter.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease.